Dyne Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Dyne Therapeutics's estimated annual revenue is currently $17.5M per year.
- Dyne Therapeutics's estimated revenue per employee is $70,625
- Dyne Therapeutics's total funding is $333M.
- Dyne Therapeutics's current valuation is $478.7M. (January 2022)
Employee Data
- Dyne Therapeutics has 248 Employees.
- Dyne Therapeutics grew their employee count by 31% last year.
Dyne Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Assistant To CEO | Reveal Email/Phone |
2 | President & CEO | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | VP, Head Translational Biomarkers | Reveal Email/Phone |
6 | VP, Head Biometrics | Reveal Email/Phone |
7 | VP, Head Technology | Reveal Email/Phone |
8 | SVP, Pharmacovigilance | Reveal Email/Phone |
9 | VP, Program Team Leader and Head New Product Planning | Reveal Email/Phone |
10 | VP, Global Head Patient Advocacy and Engagement | Reveal Email/Phone |
Dyne Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Dyne Therapeutics?
Dyne was founded with a singular focus: to transform the lives of people with serious muscle diseases by pioneering muscle-targeted therapies. Our proprietary technologies provide the foundation for breakthrough treatments. We have assembled a world-class team of experts who are united by their commitment to fulfill this mission.
keywords:N/A
$333M
Total Funding
248
Number of Employees
$17.5M
Revenue (est)
31%
Employee Growth %
$478.7M
Valuation
N/A
Accelerator
Dyne Therapeutics News
Reviewing Dyne Therapeutics (NASDAQ:DYN) and Sol-Gel Technologies (NASDAQ:SLGL). Posted by admin on Apr 23rd, 2022.
Dyne Therapeutics posted earnings per share of ($0.50) in the same quarter last year, which suggests a negative year over year growth rate of 76...
Analysts predict that Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) will post ($0.88) earnings per share (EPS) for the current quarter,...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15M | 249 | 7% | N/A |
#2 | $15M | 253 | 12% | N/A |
#3 | $75.4M | 254 | 6% | N/A |
#4 | $28.1M | 255 | 9% | N/A |
#5 | $39.7M | 256 | 2% | N/A |